Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies by Appenzeller-Herzog, Christian et al.
1 
 
Comparative effectiveness of common 
therapies for Wilson disease: A Systematic 
review and meta-analysis of controlled 
studies 
 
Christian Appenzeller-Herzog1, Tim Mathes2, Marlies L. S. Heeres3, Karl Heinz Weiss4, Roderick H. J. 
Houwen3, Hannah Ewald1,5 
1 University Medical Library, University of Basel, Basel, Switzerland  
2 Institute for Research in Operative Medicine, Faculty of Health, School of Medicine, 
Witten/Herdecke University, Cologne, Germany 
3 Wilhelmina Children's Hospital, University Medical Center Utrecht, Netherlands 
4 Department of Internal Medicine IV, Medical University of Heidelberg, Heidelberg, Germany 
5 Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, 
University Hospital Basel and University of Basel, Basel, Switzerland  
 
To whom correspondence should be addressed:  
Hannah Ewald 
Tel: +41 612075564 
Fax: not available 
Email: hannah.ewald@unibas.ch 
 
Word count:  5320 
Figures: 3 main figures, 3 supplementary figures 
Tables:  2 main tables, 5 supplementary tables 
 
Abbreviations: WD, Wilson disease; DPen, D-penicillamine; Zn, zinc salts; TTM, tetrathiomolybdate; 
OLT, orthotopic liver transplantation; NOS, Newcastle-Ottawa scale; OR, odds ratio; CI, confidence 
interval 
 
Financial support: There was no specific external funding supporting this work. 
2 
 
Conflict of Interest Statement: Four of the included reports are authored by KHW and one by RHJH. 
KHW is a consultant at Ipsen, Eisai, Chiesi, Vivet therapeutics, GMP-O, Univar, Wilson therapeutics, 
and BMS, a contract researcher of Univar, Wilson therapeutics, Novartis, QED, Alexion, and GMP-O, 
and served as a speaker at Novartis, Alexion, Falk, and Abbvie. RHJH served on an advisory board for 
Univar. All other authors declare no financial relationships with any organizations that might have an 
interest in the submitted work.  
 
Authorship Statement: CAH and HE are the guarantors. CAH, HE, and RHJH conceived the study. CAH 
and HE conducted the literature searches. CAH, HE, MLSH, and RHJH selected included studies. CAH 
and KHW extracted the data, HE checked extractions. TM analyzed the data. CAH, HE, and TM 
interpreted the results. CAH wrote the first draft and all authors made revisions on the manuscript. 
All authors read and approved the final version of the article including the authorship list.   
3 
 
Abstract 
BACKGROUND & AIMS: Wilson disease (WD) is a rare disorder of copper metabolism. The objective of 
this systematic review is to determine the comparative effectiveness and safety of common 
treatments of WD. 
METHODS: We included WD patients of any age or stage and the study drugs D-penicillamine, zinc 
salts, trientine, and tetrathiomolybdate. The control could be placebo, no treatment, or any other 
treatment. We included prospective, retrospective, randomized, and non-randomized studies. We 
searched Medline and Embase via Ovid, the Cochrane Central Register of Controlled Trials, and 
screened reference lists of included articles. Where possible, we applied random-effects meta-
analyses.  
RESULTS: The 23 included studies reported on 2055 patients and mostly compared D-penicillamine to 
no treatment, zinc, trientine, or succimer. One study compared tetrathiomolybdate and trientine. 
Post-decoppering maintenance therapy was addressed in one study only. Eleven of 23 studies were of 
low quality. When compared to no treatment, D-penicillamine was associated with a lower mortality 
(odds ratio 0.013; 95% CI 0.0010 to 0.17). When compared to zinc, there was no association with 
mortality (odds ratio 0.73; 95% CI 0.16 to 3.40) and prevention or amelioration of clinical symptoms 
(odds ratio 0.84; 95% CI 0.48 to 1.48). Conversely, D-penicillamine may have a greater impact on side 
effects and treatment discontinuations than zinc.  
CONCLUSIONS: There are some indications that zinc is safer than D-penicillamine therapy while being 
similarly effective in preventing or reducing hepatic or neurologic WD symptoms. Study quality was 
low warranting cautious interpretation of our findings.  
 
Word count: 244 
Keywords: Wilson disease; Hepatolenticular degeneration; Systematic review; Meta-Analysis  
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Introduction 
Wilson disease (WD), also known as hepatolenticular degeneration, is an autosomal recessively 
inherited disorder of copper metabolism.1, 2 It is caused by mutations in ATP7B, which encodes a 
copper transporting ATPase that is expressed in the liver.3 ATP7B-mediated copper translocation is 
essential for the excretion of copper into the bile. Defective ATP7B function will therefore result in a 
gradually increasing copper concentration in the liver, which ultimately exceeds natural buffering 
capacity.1 At that point, patients may develop acute liver failure, sometimes accompanied with 
hemolytic anemia, due to the release of unbound copper from the liver into the circulation.4 In other 
patients, liver disease develops more gradually. Copper will also disseminate to other organs, most 
notably the brain, where it causes a characteristic movement disorder.5 This is due to copper 
deposition in the basal ganglia, which are most severely affected, but a range of other neurological 
and/or psychological symptoms may also develop in response to copper overload.5  
None of the available medical treatments for WD can cure the disease and all require a life-long oral 
regimen. They aim at reducing copper overload in the body, either by the copper chelators D-
penicillamine (DPen)6 or trientine,7 which immediately increase urinary copper excretion, or by zinc 
salts (Zn),8, 9 which inhibit intestinal copper absorption through slow transcriptional induction of 
cellular metallothioneins.10 After a lag phase, Zn also induces net excretion of copper from the body.11 
Another important, emerging treatment is tetrathiomolybdate (TTM) which binds excess copper and 
promotes biliary copper excretion.12 Contrary to DPen and trientine, it not only captures free plasma 
copper but seems to have an additional protective activity component within cells.13 As it was too 
unstable for routine application in its original formulation as ammonium salt, it was never used widely. 
This may, however, change since a stable bis-choline salt has been developed and implemented 
recently.14, 15 Irrespective of the drug used, the therapy of WD can be divided into an initial de-
coppering phase with a negative copper balance and a subsequent maintenance phase where intake 
and excretion of copper roughly balance each other.1 Likewise, all of the copper-lowering drugs 
strongly require good compliance with treatment to be successful.16  
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The choice between a chelator and Zn for the treatment of copper overload in patients with WD is not 
straightforward. Owing to the low incidence and heterogeneous symptomatology of WD,1 the design 
and realization of clinical trials that compare the effectiveness of available treatment options is 
extraordinarily challenging. Thus, clinical decisions often rely more on the patient's or physician's 
preference or drug availability than on evidence. Probably mostly owing to the fact that DPen was 
introduced as a successful treatment for WD in the late 1950s – at least 30 years before any other 
treatment used today6 – it has remained the standard of care for WD patients in most countries.17 The 
dominance of DPen or, more generally, chelator therapy is also reflected in current guidelines.18-21 
These suggest that symptomatic patients should be treated with a chelating agent, although Zn may 
be used as first-line therapy in those with neurological disease.18-21 In presymptomatic patients, either 
a chelator or Zn can be used.18-21 These recommendations were partly based on a systematic review 
on initial treatment of WD from 2009 that included all studies published at that time describing 
outcome, both controlled and non-controlled.22 This systematic review was limited by the small 
number of symptomatic patients that were treated with Zn. Still, it suggested that severe side effects 
necessitating drug withdrawal were more frequent on DPen than on Zn.22 Also, neurologic 
deterioration after the start of decoppering therapy appeared to occur more frequently when using 
DPen as compared to Zn.22  
As a number of new studies that compared different treatments of WD have been published since 
2009, we now performed a systematic review focusing on controlled studies only. The aim of this 
systematic review is to assess the comparative effectiveness of common WD therapies on patient-
relevant outcomes. 
Materials and methods 
Eligibility criteria  
We included WD patients of any age or stage. The study drug had to be one of four established 
therapies, namely DPen, trientine, TTM, or Zn. The control could be placebo, no treatment, or any 
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other treatment that does not include the respective study drug (e.g. Zn versus trientine was allowed, 
Zn 50 mg versus Zn 100 mg was not). Concomitant therapies had to be identical in the compared 
treatment arms (e.g. trientine plus Zn versus TTM plus Zn). Comparisons between monotherapy and 
combination therapy regimens that included the respective monotherapy drug (e.g. DPen plus Zn 
versus Zn) have been analyzed elsewhere23 and were not considered any further here. We included 
studies that reported all-cause mortality, orthotopic liver transplantation (OLT), neurological 
symptoms (e.g. dystonia, dysarthria, cognitive decline, drooling, tremor, gait disturbance, chorea, 
seizure, psychosis), liver-related symptoms (e.g. icterus, ascites, steatosis, fibrosis, mild hepatitis, 
acute liver failure, cirrhosis, serum transaminases), adverse effects (e.g. dermatologic manifestations, 
nephrotoxicity, pulmonary toxicity, autoimmune disorders, anemia, neutrophilic agranulocytosis, 
thrombocytopenia, hypothyroidism, liver dysfunction, colitis, status dystonicus, myasthenia gravis, 
arthropathy, macromastia, early neurologic deterioration, gastrointestinal irritation), and frequency of 
treatment discontinuation (i.e. switching to another drug, stopping or changing the treatment). We 
included prospective and retrospective studies, including randomized, non-randomized controlled 
trials, and comparative observational studies that were written in English, German, Dutch, French, 
Spanish, or Portuguese. Animal studies, case reports, case series, cross-sectional studies, before-after 
studies, reviews, letters, abstract-only publications, editorials, diagnostic or other testing studies, and 
non-controlled studies were excluded. No publication date restrictions were applied.  
Identification of relevant literature 
Electronic searches 
Two information specialists (CA-H, HE) developed the search strategy. Text words (synonyms and word 
variations) and database-specific subject headings for WD, DPen, trientine, Zn, and TTM were used. 
We searched the electronic databases Medline and Embase via Ovid, and the Cochrane Central 
Register of Controlled Trials (CENTRAL) (last search January 31, 2019) (Appendix 1). All retrieved 
references were exported to Endnote X8 and deduplicated. 
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Searching other resources 
To identify possible additional studies that escaped our electronic database searches, we screened the 
reference lists of the full-text papers of all included articles and of key systematic reviews (backward 
citation chasing).24 For this purpose, we retrieved systematic reviews during title abstract screening 
that had a similar research question as we do, and that were described as “systematic (literature) 
review” (semantic variations allowed) or that described a systematic literature search in their methods 
section. 22, 23, 25-31 
Data collection and analysis 
Study selection 
Two reviewers (HE, CA-H) independently pilot-screened the first 200 references, the rest were 
screened by one reviewer (CA-H). Any uncertainties were solved by discussion (HE, CA-H). All 
potentially relevant references were retrieved in full-text and independently assessed by two 
reviewers (CA-H, RHJH). Any disagreements over eligibility were resolved by consensus. Where 
necessary, a third review author (HE) made a final judgement. We recorded the selection process and 
the reasons for exclusion of full-text articles were documented in a characteristics of excluded studies 
table (Table S1). Among included records, multiple publications on the same study were collated.  
Data extraction and management 
Study characteristics and data on predefined outcomes (see “Eligibility criteria”) from included studies 
were extracted by one reviewer (CA-H), the accuracy and correctness of the extractions were verified 
by a second reviewer (HE), and disagreements were resolved by consensus. Due to a high 
heterogeneity in outcome reporting, we used the term "asymptomatic/improved" whenever the 
interventional drug prevented or improved neurological or liver-related symptoms. For assessment of 
"asymptomatic/improved" events, there was no distinction between symptom relief and symptom 
improvement. Where available, outcome data was extracted in conjunction with the clinical 
presentation of the patients at diagnosis as reported by the authors, i.e. presymptomatic patients 
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(without clinical manifestations), and patients with hepatic, hepato-neurologic, or neurologic 
manifestations. When study cohorts included drug switcher patients, we considered patient data only 
for the first-line treatments until the time of drug switch. If the outcome was not reported at the time 
of drug switch, we censored the patient from that outcome analysis. However, for the extraction of 
mortality and OLT, we included all patients and grouped them according to their first-line treatments 
(according to the intention-to-treat principle). From two studies,32, 33 outcome data of first-line 
treatments were re-extracted from clinical files by one reviewer (KHW).  
Assessment of risk of bias in included studies 
The quality of included observational studies and non-randomized trials was assessed on study level 
using the Newcastle-Ottawa scale (NOS) for cohort studies by one reviewer (CA-H). The scale applies a 
semi-quantitative star system (0 – 9 stars, with more stars indicating higher quality) to estimate study 
quality in the three domains subject selection, comparability of cohorts, and assessment of outcome.34 
Quality appraisal of randomized controlled trials was conducted using the RoB 2.0 tool which was 
developed by the Cochrane collaboration.35  
Statistical analysis 
We performed a meta-analysis for pooling odds ratios (ORs) for studies that were considered 
sufficiently clinical homogenous. The primary outcomes were mortality and asymptomatic/improved, 
the secondary outcomes side effects, early neurologic deterioration, treatment discontinuation, and 
OLT. In the case that at least six studies without zero events could be included in the meta-analysis,36, 
37 we performed inverse-variance random effects meta-analyses using the Paule-Mandel between 
study heterogeneity estimator with modified Hartung-Knapp confidence intervals (CIs).38, 39 For 
consistency, we used the same model for sensitivity analyses irrespective of the number of studies. 
For any comparison with zero events or less than six included studies, we used beta-binomial models 
which show satisfactory statistical properties for pooling sparse data.40 In addition to the beta-binomial 
models, we performed sensitivity analyses using the Peto-Method because effect estimates and 
confidence intervals can strongly depend on the applied meta-analytic method in sparse data and 
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unbalanced study arm situations.41 For all pooled ORs, we calculated 95% CIs. Statistical heterogeneity 
was quantified with I2.42 If the I2 value was >0%, we calculated 95% prediction intervals in addition to 
the 95% CIs.43 We performed sensitivity analyses according to methodological study quality if at least 
five moderate to high quality studies (NOS score <6 as was rated as low quality and ≥6 as moderate to 
high quality44) were available. Subgroup analyses according to clinical presentation were added when 
at least three studies reported subgroup-specific outcome data. We could not prepare funnel-plots 
because all comparisons included less than ten studies.  
For inverse-variance random effects and Peto-odds-ratios meta-analyses, we used the R package 
meta.45 We performed meta-analyses based beta-binomial models with SAS© Version 9.4. For the 
graphical representation of beta-binomial analyses, we generated forest plots in R using the fixed-
effect inverse variance model and manually inserted the summary OR derived from the beta-binomial 
model.  
Results 
Results of the search and study characteristics 
Our electronic searches identified 3453 records and three potentially eligible additional records were 
found using backward citation chasing. Eight potentially relevant records were excluded due to foreign 
language.46-53 A total of 174 records were selected for full-text screening to assess eligibility. Of these, 
26 publications reporting on 23 studies met our inclusion criteria (Figure 1).17, 26, 32, 33, 54-73 Reasons for 
exclusion of the 148 studies are shown in Table S1.  
The included studies were published between 1968 and 2018. Seventeen were retrospective 
observational studies, three were prospective observational studies, two were non-randomized 
controlled trials, and one was a randomized controlled trial (Table 1). Given the substantial ambiguity 
in the classification of observational studies,74 we refrained from defining observational study designs 
any further.  
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From the included studies (Table 1), four compared the use of DPen with no treatment54-56, 59 (of which 
one study55 used a mixture of DPen and L-penicillamine, the less-active stereoisomer of DPen). Four 
compared DPen with trientine or Zn,33, 70, 73, 75 eleven compared DPen with Zn,17, 26, 57, 60, 62, 64, 67-69, 71, 76 
and two DPen with trientine.32, 61 Finally, two stand-alone studies evaluated the performance of DPen 
versus succimer treatment during maintenance phase58 and trientine versus TTM treatment as initial 
therapy,63 respectively. In both studies, all patients received Zn treatment concomitantly to the drugs 
under evaluation. Only two57, 64 of the 26 included publications were already analyzed in the previous 
systematic review on optimal initial treatment of Wilson’s disease.22  
The studies included 2055 patients, whereas a partial overlap of cohorts was identified between three 
studies from Heidelberg, Germany,32, 33, 73 and two studies from Naples, Italy.60, 71 Some studies 
exclusively included presymptomatic,55 hepatic,26, 59, 71, 76 neurologic,63 or symptomatic17, 64, 67, 70 (i.e. 
with any manifestations) patients (Table 1). The age range across all studies was 1 to 66 years; 17/23 
studies included mixed populations while five studies reported on children60, 71 or adults17, 68, 76 only. 
Mortality,17, 54-57, 59, 61-64, 71, 76 "asymptomatic/improved",17, 32, 33, 54, 57, 58, 60, 64, 68, 69, 71 side effects,32, 33, 57, 58, 
60, 61, 63, 64, 68, 69, 71 and treatment discontinuation17, 32, 33, 57, 58, 60, 61, 64, 68, 69, 71, 75, 76 were the most prevalent 
outcomes, followed by OLT59-61, 64, 69, 71, 76 and neurologic deterioration17, 32, 33, 63, 64, 71 (Table 1). Data on 
fibrosis progression,26, 70 development of autoimmune diseases,73 and 15-year probability of survival67 
were reported in stand-alone studies only. The maintenance phase of drug therapy was specifically 
addressed in only one study.58 
Methodological study quality rating 
The NOS scores ranged between 2 and 8 with a median score of 5.5 (Table S2), indicating that only a 
subset of studies were of high or moderate quality. Potential problems with the representativeness of 
included patients and comparability of patients between different treatment arms (selection bias) 
were identified in 9 of 21 studies (38%).26, 33, 56, 59, 61, 67, 69, 71, 76 Only four studies reached a NOS score > 
7, which is indicative of high reliability.17, 54, 57, 70 Adjusting for confounding factors was reported in only 
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one study.17 Quality assessment of Brewer et al.63 using RoB 2.0 identified some concerns with regard 
to bias due to the randomization process, due to missing outcome data, and in the selection of the 
reported results (Table S2).  
Data synthesis and analysis 
D-Penicillamine versus no treatment 
In the four studies comparing DPen-treated and untreated WD patients,54-56, 59 the pooled OR for death 
was 0.013 (95% CI 0.0010 to 0.17; I2=31%; Figure 2, Table 2). The pooled OR for remaining or becoming 
asymptomatic was 22.3 (95% CI 0.40 to >100; I2=86%; Table 2).54-56 Other outcomes were not reported 
for this comparison. Due to the low number of studies no sensitivity or subgroup analyses were 
performed.  
D-Penicillamine versus zinc salts 
The pooled OR for mortality from seven studies17, 33, 57, 62, 64, 71, 76 was 0.73 (95% CI 0.16 to 3.40; I2=37%; 
Figure 3A, Table 2). For the asymptomatic/improved outcome, meta-analysis of seven studies17, 33, 57, 
60, 64, 68, 69 yielded an OR of 0.84 (95% CI 0.48 to 1.48; I2=0%; Figure 3B, Table 2). 
The pooled OR for OLT60, 64, 69, 76 was 1.74 (95% CI 0.066 to 46.0; I2=37%; Table 2). Side effects33, 57, 60, 64, 
68 and neurologic deterioration17, 33, 64, 71 yielded ORs of 3.28 (95% CI 0.542 to 19.9; I2=24%; Figure S1, 
Table 2) and 3.71 (95% CI 0.42 to 32.7; I2=10%; Figure S2, Table 2), respectively. The pooled OR of 
treatment discontinuation17, 33, 57, 60, 64, 68, 69, 75, 76 was 2.96 (95% CI 1.14 to 7.66; I2=48%; Figure S3, Table 
2).  
One study found more patients treated with DPen (6/91, 6%) to develop autoimmune diseases as 
compared to Zn (0/58) or trientine (0/58).73 One study detected no difference between DPen- and Zn-
treated patients for the 15-years probability of survival (78 ± 6% vs. 67 ± 17%).67 Focusing on 
progression of liver fibrosis, one study found a higher rate of progression in the DPen group (1/14, 7%) 
compared to Zn (0/3).70 Another study found a higher rate of progression in the Zn group (2/5, 40%) 
compared to DPen (0/3).26 Extracted outcome data from individual studies are reported in Table S3. 
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Sensitivity analyses using the Peto-Method or excluding low quality studies did not fundamentally 
change the results (Table 2). However, the results from the Peto-Method suggested that DPen may 
have a higher frequency of side effects, neurologic deterioration, and treatment discontinuation than 
Zn (Table 2). Subgroup analyses according to the clinical presentations "hepatic" and "(hepato-
)neurologic" also did not fundamentally change the results (Table 2). Other sensitivity or subgroup 
analyses including presymptomatic patients were not possible due to the low number of studies.  
Other comparisons 
There were not enough studies comparing other drug combinations to perform meta-analysis. For the 
comparisons trientine with DPen and trientine with TTM, the authors found no difference in 
effectiveness in primary outcomes.32, 63 However, they found early neurologic deterioration to occur 
more frequently under therapy with trientine (5/16, 31% or 6/23, 26%) as compared to DPen (8/97, 
8%)32 or TTM (1/25, 4%).63 At the same time, the relative risk for side effects was found to be lower 
under trientine therapy (9/38, 24% or 1/23, 4%) compared to DPen (182/295, 62%)32 or TTM (7/25, 
28%).63 For the comparison between DPen and succimer in the maintenance phase, higher 
effectiveness (49/60, 82% versus 35/60, 58%) and fewer side effects (9/60, 15% versus 22/60, 37%) 
and treatment discontinuations (11/60, 18% versus 25/60, 42%) were reported for succimer (Table 
S3).58  
Discussion 
Summary of evidence 
In the present review, we aimed to assess the comparative effectiveness of common WD therapies on 
patient-relevant outcomes. For the comparison of DPen versus no treatment, we found a strong 
association between DPen and reduced mortality. Given the commonplace that WD was a fatal disease 
up until the institution of DPen therapy, this result is merely confirmatory. Although DPen therapy as 
opposed to no treatment is known to be associated with prevention or remission of clinical symptoms, 
the corresponding meta-analysis with a prediction interval of 0 to 2.1 x 1015 could not confirm the 
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clinical experience. This was, however, strongly affected by study heterogeneity and selection bias, as 
one study included only presymptomatic subjects.55  
For the comparison of DPen versus Zn, we found no evidence for a difference in mortality, clinical 
symptoms, OLT, side effects, and neurologic deterioration. For side effects, this lack of evidence could 
be explained by one outlier study64 (Figure S1). In this study, four patients in the Zn arm with 
gastrointestinal irritations were counted as events, although two of those four were subsequently 
switched from Zn-sulphate to Zn-acetate with favorable outcome (see Limitations section for further 
discussion). Results from sensitivity and subgroup analyses were mostly confirmative, although 
depending on the analysis used, DPen appeared to have a higher impact on side effects and neurologic 
deterioration than Zn – which lines up with previous conclusions.22 However, DPen may be associated 
with more treatment discontinuations than Zn, although data were heterogeneous. We found no 
indication for subgroup effects in the hepatic and (hepato-)neurologic subgroups. Further inspection 
of the data suggested that, contrary to Zn, the principal reason for DPen treatment discontinuations 
may have been the appearance of side effects (Table S3 and data not shown). We emphasize that due 
to moderate/low study quality and heterogeneity, the results from our meta-analyses should in 
general be interpreted cautiously and graded as low evidence.  
One reason why we may not have detected a difference in effectiveness between DPen and Zn may 
be due to our decision to restrict analyses to the first treatment block, considering that subsequent 
treatment blocks are confounded by treatment history. This may also be the reason why our findings 
deviate from previous conclusions that Zn is not as effective as chelator therapy.33 Another reason may 
be our choice of analysis: The more conservative beta-binomial meta-analysis but not the Peto-Method 
resulted in wide confidence intervals crossing the null in most secondary outcomes. Such inconsistency 
in results across different models reflects once more the considerable clinical and statistical 
heterogeneity of the included studies.  
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During our review of all included studies that compared chelator and Zn treatments, we noticed that 
several authors explicitly indicated Zn as the optimal primary treatment option for certain patient 
groups including presymptomatic and neurologic patients. Interestingly, several authors’ 
recommendations thus stand in contrast to the recommendations in current guideline publications 
(recommendations and guideline recommendations in Table S4). During title/abstract screening, we 
also flagged all single-arm studies that investigated Zn monotherapy.77-84 Most of these studies 
reported positive effects of Zn. The present review also indicates Zn to display a favorable safety profile 
and prevent or relieve symptoms in a similar manner as chelator-therapy would, although results were 
not definitive. However, Zn induces copper excretion indirectly via blocking of intestinal copper 
absorption, which is a slow-acting mechanism that takes a few weeks or months to be effective.10 
Hence, using only Zn is not a suitable therapy for patients experiencing acute copper toxicity. A 
decoppering phase with a chelator applied together with Zn and followed by Zn monotherapy, as 
introduced by Brewer,63 may therefore constitute a suitable treatment regimen and form a precedent 
for future guideline formulation. Alternatively, the non-permanent introduction of a chelator to a 
patient under long-term Zn treatment33 may prove useful in case of unmitigated copper toxicity.  
Recently, a new formulation of TTM called WTX101 was developed and successfully run through a 
phase 2 trial.14 The subsequent phase 3 trial comparing WTX101 with standard of care (chelation or Zn 
therapy or a combination of both chelation and Zn therapy) is currently running.15 A major advantage 
of WTX101 is the once-daily dosing scheme14 (compared to the more complex 2-times a day dosing 
scheme under DPen19) which could positively impact on patients’ compliance and life-long copper 
control. In the same vein, efforts have been made to validate a once-daily dosing scheme of trientine 
for maintenance treatment,85 which currently requires a 2-times dosing scheme.19 Similar dosing 
simplification has unfortunately not yet been achieved for Zn which requires at least two doses per 
day to be effective.78 However, some pre-work towards an extended-release formulation of Zn has 
been published.86  
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Conspicuously, only one of the studies included in this review addressed the maintenance phase of 
WD therapy comparing DPen+Zn to succimer+Zn.58 None of the included studies reported on Zn 
compared to control treatment in the maintenance phase, although Zn is recommended for 
maintenance treatment almost throughout all international guidelines (Table S4). During title/abstract 
screening, we identified some single-arm observational studies that documented the potential 
suitability of Zn for maintenance therapy.87-92 One reason for the paucity of controlled data on 
maintenance treatment may be that the field appears to be lacking consensus on the definition of 
maintenance therapy, i.e. when a patient is “adequately decoppered”.20  
A further interesting observation we made in included studies was concerned with patients with 
hepatic symptoms. Several study authors reported an apparent lack of correlation between elevated 
serum transaminase levels and actual severity of liver disease (Table S5)26, 33, 60, 64, 70 (a correlation that 
is usually found in the context of liver disease93 but may be corrupted in WD due to a predominance 
of apoptotic over necrotic hepatocyte death94, 95). Yet, within these very studies, the rating of 
treatment success was often, sometimes even exclusively, based on serum transaminase levels. In light 
of possible lack of correlation between serum transaminase levels and actual severity of liver disease 
such rating may in fact be misleading. Alternative liver function tests such as other laboratory values 
(bilirubin, prothrombin time, ammonia, non-ceruloplasmin bound copper) as well as liver stiffness 
measurements and histological findings should complement the time course analyses of serum 
transaminases in WD patients. Currently, there is no consensus on a composite of clinical and 
biochemical markers of liver function to be used to guide treatment decisions.  
Future research 
Future research should consider applying modern methodology such as the combination of 
randomization and use of routinely collected data. Randomization of the treatment would increase 
comparability of the groups, reduce selection bias, and facilitate causal conclusions from the study 
results. As such, the results of the ongoing phase 3 trial comparing WTX101 to other common 
treatments are highly awaited.15 Given the results of this review and the paucity of controlled clinical 
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data concerning the maintenance phase of WD treatment, it would be highly desirable though to 
compare the WTX101 group of maintenance phase patients to a clean Zn group of randomly allocated 
patients (not to a heterogeneous “standard of care” group). So far, a direct comparison of these two 
drugs is missing from the literature and clinical decisions concerning the maintenance phase of therapy 
are hardly supported by evidence.  
Further research is also needed to unravel the multifaceted factors that influence serum transaminase 
levels in WD patients and to delineate a reliable biomarker repertoire for the monitoring of liver 
function in WD. Likewise, we are still lacking a definitive answer as to which treatment is associated 
with the lowest risk for early neurologic deterioration (see below), warranting further studies with 
more precise reporting. And finally, also less common WD drugs such as Chinese herbals28 and 
succimer58 could be included in future comparative investigations.  
Limitations 
First, the conclusions of our meta-analyses mainly suffer from the fact that high-quality evidence for 
the comparative effectiveness and safety of WD therapies is scarce. Although DPen and Zn treatment 
of WD patients has been compared in a fair number of studies, there is not a single randomized 
controlled trial comparing the two treatments. Moreover, study arms were frequently unbalanced 
with a bias towards more patients being treated with DPen (Table 1). 
Second, all studies but one did not statistically correct for any confounding factors. Some factors seem 
likely to be confounding factors such as age, clinical presentation, disease stage during diagnosis, or 
the specialization of the referral center performing the study, i.e. neurologic versus hepatic versus 
pediatric clinics. The probably most severe limitation, however, comes from selection bias when e.g. 
study authors would generally prescribe Zn to presymptomatic patients69 or DPen to patients with 
hepatic symptoms.71 We have tried to address some of these limitations by performing sensitivity 
analyses based on the NOS scores of the studies.  
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Third, a common yet very limiting problem we encountered were non-uniform definitions of 
outcomes. We tried to assess early neurologic deterioration which is often reported as a side effect in 
response to treatment initiation in WD patients with neurologic presentation.72, 96 Early neurologic 
deterioration is thought to occur more frequently in chelator-treated as compared to Zn-treated 
patients.22 In the four studies comparing the effect of DPen versus Zn on neurologic deterioration, 
differing or intransparent definitions and time windows were used for the scoring of symptoms. Hence, 
we meta-analyzed “neurologic deterioration” in general rather than early neurologic deterioration. In 
light of these limitations, our meta-analysis on neurologic deterioration for the comparison DPen 
versus Zn should be interpreted with care. It should further be noted that trientine – while apparently 
the chelator of choice with respect to side effects in general – appears to confer an overproportionally 
high risk of early neurologic deterioration.32, 63 Another example for non-uniform outcome definitions 
was the scoring of clinical symptoms which was rarely standardized according to published scales.97-99 
We therefore extracted the binary outcome "asymptomatic/improved" for whenever neurological or 
liver-related symptoms were reported to be prevented or improved.  
Fourth, we did not assess the severity of different side effects. Thus, relatively mild gastrointestinal 
irritations which are prevalent among Zn-treated patients (data not shown) were scored equally to 
severe and irreversible autoimmune disorders or nephrotoxicity which are relatively common among 
DPen-treated patients (data not shown). Accordingly, our meta-analysis on side effects lends 
conservative support only to the notion that Zn is safer than DPen.  
Fifth, we did not extract dosing regimens of the WD therapies. Our main reason for neglecting this data 
was that we did not want to conduct further analyses on the already highly biased, low quality studies 
and risk any chance findings. Hence, we cannot exclude an impact of differing dosing regimens on the 
effect estimates.  
18 
 
Sixth, we did not differentiate between the use of different zinc salts such as zinc acetate, zinc sulphate, 
and zinc gluconate. This is potentially meaningful, as zinc sulfate may cause more gastrointestinal side 
effects than zinc acetate.64, 68, 100  
Conclusions 
There is not enough evidence to claim superiority of one common WD treatment over the other, a firm 
basis of controlled clinical data is lacking completely. However, there are some indications that Zn has 
less side effects and lower treatment discontinuation rate than DPen therapy while being similarly 
effective. We emphasize that due to low study quality our results should be interpreted cautiously. 
Future research should focus on higher study quality and reporting. 
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Tables 
Table 1: Characteristics of included studies: Overview 
 
First author 
country 
 year 
Study design Patient 
population,  
study duration 
Treatment 
comparison 
Outcome(s) Presentation Patients (n)  
[original sample size] 
Goldstein United 
States 196854 
retrospective 
observational 
study 
* Cases prior 
1958: no Dpen 
available 
* 3 sibling pairs 
* Mean age 26 (5-
48) y 
* Mean TD 58 (1-
114) mo 
Dpen 
vs.  
no treatment 
mortality 
asymptomatic/ 
improved 
all 
presymptomatic (Dpen) 
hepatic (Dpen) 
hepato-neurologic 
(Dpen) 
neurologic (Dpen) 
 
hepatic (-) 
hepato-neurologic (-) 
23[26]  
2[2] 
1[1] 
 
4[5] 1 too early for evaluation 
14[15] 1 too early for evaluation 
 
1[2] 1 lost to FU 
1[1] 
 
Excluded from original sample size:  
1 patient dimercaprol 
Sternlieb  
United States 
196855 
retrospective 
observational 
study 
* Presymptomatic 
patients with 
family history 
and/or 
established WD 
diagnosis 
* No Dpen, if 
Dpen not 
available or 
diagnosis only 
presumptive 
* Mean age 9 (1-
34) y 
* Mean FU 44 (6-
108) mo 
Dpen or 
D/Lpen 
vs.  
no treatment 
mortality 
asymptomatic 
all 
presymtomatic (Dpen or 
D/Lpen) 
 
presymtomatic (-) 
53[53] 
 
42[42] 
 
11[11] 
Strickland 
Taiwan/ 
United Kingdom 
197356 
retrospective 
observational 
study 
* WD diagnosis 
partially done 
post-mortem 
* Including sibling 
pairs 
* Frequently, 
Dpen not 
available (despite 
WD diagnosis) 
* Mean age 15 (5-
47) y 
* Mean TD 126 (1-
180) mo 
Dpen 
vs.  
no treatment 
mortality 
asymptomatic 
all 
presymtomatic (Dpen) 
symptomatic (Dpen) 
 
presymtomatic (-) 
symptomatic (-) 
88[88] 
16[16] 
35[35] 
 
1[1] 
36[36] 
 
Excluded from original sample size:  
54 patients FU uncompleted 
Durand 
France/Israel/ 
Switzerland 
200159 
retrospective 
observational 
study 
* All patients had 
liver injury, non-
WD causes of liver 
injury excluded 
* Manifestations 
less than 2 mo 
before admission 
* Cases prior 
1979: No Dpen 
because 
considered 
ineffective 
* Mean age 17 (8-
22) y 
* Mean FU 72 (3-
144) mo 
Dpen 
vs.  
no treatment 
mortality 
OLT 
all 
hepatic (Dpen) 
 
hepatic (-) 
17[17] 
11[11] 
 
6[6] 
Weiss  
Germany/ 
Austria  
201133† 
(Merle, 200765)† 
retrospective 
observational 
study 
* WD diagnosis 
1954-2008 
* Patients 
referring to 
hepatology 
centers 
Dpen 
vs.  
Trientine 
vs.  
Zn-
(sulfate/aceta
te) 
mortality 
asymptomatic/ 
improved 
side effects 
treatment 
discontinuation 
all 
presymptomatic (Dpen) 
hepatic (Dpen) 
hepato-neurologic 
(Dpen) 
neurologic (Dpen) 
 
267[267] 
29[29] 
131[131] 
 
19[19] 
41[41] 
29 
 
* Treatment for ≥ 
6 mo 
* Median age 18 
(1-57) y 
* Median FU 205 
(5-649) mo 
neurologic 
deterioration 
presymptomatic 
(Trientine) 
hepatic (Trientine) 
hepato-neurologic 
(Trientine) 
neurologic (Trientine) 
 
hepatic (Zn) 
neurologic (Zn) 
 
 
1[1] 
13[13] 
 
5[5] 
5[5] 
 
18[18] 
5[5] 
 
Excluded from original sample size:  
21 patients Zn+chelator 
Sini  
Italy  
201370 
retrospective 
observational 
study 
* WD diagnosis 
* Patients 
referring to 
hepatology center 
* Consent to 
serial liver 
biopsies 
* Mean age 23 (5-
51) y 
* Median FU 300 
(NR) mo 
Dpen 
vs. Trientine 
vs. Zn 
(sulfate/actat
e) 
fibrosis 
progression 
all 
hepatic (Dpen) 
hepato-neurologic 
(Dpen) 
 
hepatic (Trientine) 
 
hepatic (Zn) 
hepato-neurologic (Zn) 
17[23] 
12[16] 4 switchers  
 
2[3] 1 switch trientine 
 
0[1] 1 switch Zn 
 
1[1] 
2[2] 
 
Excluded from original sample size:  
17 patients combination therapy 
Seessle Germany  
201673† 
retrospective 
observational 
study 
* WD diagnosis 
1998-2009 
* Patients 
referring to 
hepatology center 
* Treatment for ≥ 
6 mo 
Dpen 
vs.  
Trientine 
vs.  
Zn-
(sulfate/actat
e) 
autoimmune 
diseases 
all 
any (Dpen) 
any (Trientine) 
any (Zn) 
207[207] 
91[91] 
58[58] 
58[58] 
Tai  
Taiwan  
201875 
retrospective 
observational 
study 
* Random sample 
from national 
database 2000-
2011 
* WD subjects 
identified 
according to ICD-9 
code 275.1 
* Median age 25 
(3-63) y 
* Median FU 78 
(5-146) mo 
Dpen 
vs.  
Trientine 
vs.  
Zn 
treatment 
discontinuation 
all 
any (Dpen) 
any (Trientine) 
any (Zn) 
37[66] 
25[54] 5 switch trientine, 24 switch Zn 
4[4] 
8[8] 
Czlonkowska 
Poland  
199657 
non-
randomized 
controlled 
trial 
* WD diagnosis 
since 1980 
* Fully compliant 
* Patients 
referring to 
neurological 
center 
* Mean age 29 
(NR) y 
* Mean FU 58 
(NR) mo 
Dpen 
vs.  
Zn-sulfate 
asymptomatic/ 
improved 
mortality 
side effects 
treatment 
discontinuation 
all 
presymptomatic (Dpen) 
hepatic (Dpen) 
neurologic (Dpen) 
 
presymptomatic (Zn) 
hepatic (Zn) 
neurologic (Zn) 
48[67] 
2[3] 1 switch Zn 
3[4] 1 switch Zn 
14[27] 13 switch Zn 
 
8[8] 
3[3] 
18[22] 4 switch Dpen 
Iorio  
Italy  
200460‡ 
retrospective 
observational 
study 
* WD diagnosis 
1979-2001 
* Patients 
referring to 
paediatric 
departments 
* Treatment for ≥ 
12 mo 
* Median age 7 
(1-18) y 
* Median TD 76 
(12-271) mo 
Dpen 
vs.  
Zn-sulfate 
asymptomatic/ 
improved 
side effects 
OLT 
treatment 
discontinuation 
all 
presymptomatic (Dpen) 
hepatic (Dpen) 
neurologic (Dpen) 
 
presymptomatic (Zn) 
hepatic (Zn) 
neurologic (Zn) 
109[109] 
3[3] 
80[80] 
4[4] 
 
4[4] 
16[16] 
2[2] 
Czlonkowska 
Poland  
200562 
prospective 
observational 
study 
* WD diagnosis 
1992-2003 
* Patients 
referring to 
neurological 
center 
Dpen 
vs.  
Zn-sulfate 
mortality all 
any (Dpen) 
any (Zn) 
any (-) 
160[164] 
79[79] 
81[81] 
0[4] 4 diagnosis too late 
30 
 
* Mean age 25 
(NR) y 
Medici  
Italy  
200664 
retrospective 
observational 
study 
* WD diagnosis 
since 1980 
* Mean age 16 (4-
35) y 
* Mean FU 180 
(NR) mo 
Dpen 
vs.  
Zn-sulfate 
(acetate) 
asymptomatic/ 
improved 
side effects 
treatment 
discontinuation 
early neurologic 
deterioration 
OLT 
mortality 
all 
hepatic (Dpen) 
hepato-neurologic 
(Dpen) 
 
hepatic (Zn) 
hepato-neurologic (Zn) 
35[35] 
15[15] 
 
8[8] 
 
8[8] 
4[4] 
Svetel  
Serbia  
200967 
prospective 
observational 
study 
* WD diagnosis 
1980-2007 
* Symptomatic 
patients 
* Mean age 24 
(NR) y 
* Mean FU 133 
(NR) mo 
Dpen 
vs.  
Zn-sulfate 
15 year 
probability of 
survival 
all 
symptomatic (Dpen) 
symptomatic (Zn) 
89[89] 
79[79] 
10[10] 
 
Excluded from original sample size:  
32 patients Zn+Dpen 
Cope-Yokoyama 
Italy  
201026 
prospective 
observational 
study 
* WD diagnosis 
1981-2006 
* Patients 
referring to 
hepatology center 
* Consent to 
serial liver 
biopsies 
* No alcohol 
abuse, hepatitis 
virus, or 
metabolic 
syndrome 
* Mean age 17 (6-
35) y 
* Mean FU (12-
144) mo 
Dpen 
vs.  
Zn-sulfate 
fibrosis 
progression 
all 
hepatic (Dpen) 
hepatic (Zn) 
11[12] 
5[5] 
6[7] 1 switch Dpen 
Bruha  
Czech Republic 
201168 
retrospective 
observational 
study 
* WD diagnosis 
1965-2008 
* Mean age 39 
(16-63) y 
* Mean FU 181 
(12 492) mo 
Dpen 
vs.  
Zn-
(sulfate/aceta
te) 
asymptomatic/ 
improved 
side effects 
treatment 
discontinuation 
all 
presymptomatic (Dpen) 
hepatic (Dpen) 
neurologic (Dpen) 
 
presymptomatic (Zn) 
hepatic (Zn) 
neurologic (Zn) 
93[112] 
8[9] 1 switch Zn 
34[40] 6 switch Zn 
38[50] 12 switch Zn 
 
2[2] 
8[8] 
3[3] 
 
Excluded from original sample size:  
3 patients with OLT and no treatment 
2 patients Zn+Dpen 
Rodriguez  
Spain  
201269 
retrospective 
observational 
study 
* WD diagnosis 
1975-2010 
* Including 
siblings 
* Comorbidities in 
>50% of patients 
* Symptomatic 
patients treated 
with Dpen 
* Median age 22 
(6-50) y 
* Median FU 168 
(24-408) mo 
Dpen 
vs.  
Zn 
asymptomatic/ 
improved 
side effects 
treatment 
discontinuation 
OLT 
hepatic (Dpen) 
hepato-neurologic 
(Dpen) 
neurologic (Dpen) 
 
presymptomatic (Zn) 
10[10] 
 
3[3] 
5[5] 
 
2[2] 
Ranucci  
Italy  
201471‡ 
retrospective 
observational 
study 
* WD diagnosis in 
childhood (1984-
2012) 
* Patients 
referring to 
hepatology center 
with mild liver 
disease 
* Symptomatic 
patients 
preferentially 
treated with Dpen 
Dpen 
vs.  
Zn-
(sulfate/aceta
te) 
asymptomatic/ 
improved 
side effects 
neurologic 
deterioration 
treatment 
discontinuation 
mortality 
OLT 
all 
hepatic (Dpen) 
hepatic (Zn) 
42[42] 
27[27] 
15[15] 
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* Treatment for ≥ 
6 mo 
* Median age 6 
(1-16) y 
* Median FU 144 
(19-302) mo 
Czlonkowska 
Poland  
201417 
(Litwin, 201572) 
retrospective 
observational 
study 
* WD diagnosis in 
adulthood (2005-
2009) 
* Patients 
referring to 
neurological 
center 
* Symptomatic 
patients 
* Median age 22-
33 (NR) y 
* Median FU 48 
(NR) mo 
Dpen 
vs.  
Zn-sulfate 
asymptomatic/ 
improved 
side effects 
treatment 
discontinuation 
mortality 
early neurologic 
deterioration 
all 
hepatic (Dpen) 
neurologic (Dpen) 
 
hepatic (Zn) 
neurologic (Zn) 
143[143] 
36[36] 
35[35] 
 
51[51] 
21[21] 
Vieira Barbosa 
Switzerland 
201876 
retrospective 
observational 
study 
* WD diagnosis in 
adulthood (2004-
2016) 
* Patients 
referring to 
hepatology center 
* Symptomatic 
patients 
* Median age 26 
(18-56) y 
Dpen 
vs.  
Zn-acetate 
Treatment 
discontinuation 
mortality 
OLT 
all 
hepatic (Dpen) 
 
hepatic (Zn) 
3[8] 
3[6] 3 switch trientine 
 
0[2] 2 switch Dpen 
 
Excluded from original sample size:  
2 patients with OLT and no treatment 
Kumagi 
 Japan  
200461 
retrospective 
observational 
study 
* WD diagnosis 
1976-2003 
* All patients 
showed hepatic 
manifestations 
* No hepatitis 
virus in most 
patients 
* 4 cases with 
family history and 
4 siblings 
* Mean age 32 (9-
66) y 
* Median FU 48 
(1-180) mo 
Dpen 
vs.  
Trientine 
mortality 
OLT 
side effects 
treatment 
discontinuation 
all 
presymptomatic (Dpen) 
hepatic (Dpen) 
hepato-neurologic 
(Dpen) 
 
hepatic (T) 
13[16] 
1[1] 
10[10] 
 
4[4] 
 
1[1] 
Weiss 
 Germany/ 
Austria/ 
Eurowilson, 
201332† 
retrospective 
observational 
study 
* WD diagnosis 
1956-2010 
* Patients 
referring to 
tertiary care 
centers or under 
trientine 
monotherapy 
from 
EUROWILSON 
registry 
* Treatment for ≥ 
6 mo 
* Median age 18 
(1-60) y 
* Median FU 160 
(NR) mo 
Dpen 
vs.  
Trientine 
asymptomatic/ 
improved 
side effects 
treatment 
discontinuation 
early neurologic 
deterioration 
all 
presymptomatic (Dpen) 
hepatic (Dpen) 
hepato-neurologic 
(Dpen) 
neurologic (Dpen) 
 
presymptomatic 
(trientine) 
hepatic (trientine) 
hepato-neurologic 
(trientine) 
neurologic (trientine) 
333[333] 
48[48] 
150[150] 
 
31[31] 
66[66] 
 
 
2[2] 
20[20] 
 
7[7] 
9[9] 
 
Excluded from original sample size:  
72 first-line treatments other than Dpen 
or trientine 
Ren  
China  
199858 
non-
randomized 
controlled 
trial 
* WD diagnosis 
1994-1997 
* Trial on 
maintenance 
treatment 
(patients initially 
treated with 
unithiol or EDTA) 
* Mean age 19 
(NR) y 
Dpen+Zn-
gluconate 
vs. 
Succimer+Zn-
gluconate 
asymptomatic/ 
improved 
side effects 
treatment 
discontinuation 
all 
presymptomatic (Dpen) 
hepatic (Dpen) 
neurologic (Dpen) 
 
presymptomatic 
(Succimer) 
hepatic (Succimer) 
neurologic (Succimer) 
120[120] 
10[10] 
9[9] 
41[41] 
 
 
10[10] 
10[10] 
40[40] 
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* Mean FU 18 (6-
36) mo 
Brewer 
 United States/ 
Canada  
200663 
(Brewer, 200866) 
randomized 
controlled 
trial 
* Start of 
enrollment 1994 
* Symptomatic 
patients  
* Treatment-
naive or chelator 
treatment for < 
28 d or long-term 
treatment 
stopped for > 1 y 
with development 
of new symptoms 
* Trial on initial 
treatment 
(patients 
subsequently  
treated with Zn-
acetate for 
maintenance) 
* Mean age 28 
(13-49) y 
* TD 2 mo 
Trientine+Zn-
acetate 
vs. TTM+Zn-
acetate 
early neurologic 
deterioration 
mortality 
side effects 
all 
neurologic (Trientine) 
neurologic (TTM) 
48[48] 
23[23] 
25[25] 
 
† likely cohort overlap (Heidelberg University Hospital) 
‡ likely cohort overlap (University of Naples) 
Age, age at admission; DPen, D-penicillamine; d, days; EDTA, ethylenediaminetetraacetic acid; FU, follow-up; 
mo, months; NR, not reported; OLT, orthotopic liver transplantation; TD, treatment duration; TTM, 
tetrathiomolybdate; WD, Wilson's disease; y, years; Zn, zinc salts. 
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Table 2: Summary of results 
Outcome # studies # patients Method Effect estimate 
(OR) 
95% CI I2 (%) Prediction 
interval 
D-Penicillamine versus no treatment 
Mortality 4 125 versus 52 BBIN 0.013 0.0010 to 0.17 31 0 to 0.53 Peto 0.02 0.01 to 0.05 
Asymptomatic 3 114 versus 50 BBIN 22.3 0.40 to 1.2 x 10
3 
86 0 to 2.1 x 1015 Peto NA NA 
D-Penicillamine versus zinc salts 
Mortality 7 460 versus 238 BBIN 0.73 0.16 to 3.40 37 0.01 to 71.46 Peto 1.14 0.55 to 2.33 
Asymptomatic/improved 7 518 versus 173 PM-HK 0.84 0.48 to 1.48 0 NA 
Asymptomatic/improved (sensitivity†) 5 280 versus 148 PM-HK 0.96 0.43 to 2.14 12 0.31 to 2.98 
Asymptomatic/improved  
(subgroup: hepatic) 5 243 versus 100 
BBIN 0.59 0.16 to 2.14 0 NA Peto 0.65 0.34 to 1.25 
Asymptomatic/improved  
[subgroup: (hepato-)neurologic] 4 141 versus 43 
BBIN 0.79 0.15 to 4.14 0 NA Peto 0.99 0.40 to 2.46 
OLT 4 134 versus 38 BBIN 1.74 0.066 to 46.0 37 0 to 502.6 Peto 0.68 0.13 to 3.40 
Side effects 5 463 versus 103 BBIN 3.28 0.54 to 19.9 24 0.64 to 19.28 Peto 3.68 2.10 to 6.43 
Neurologic deterioration 4 130 versus 45 BBIN 3.71 0.42 to 32.7 10 0.22 to 40.02 Peto 2.86 1.18 to 6.93 
Treatment discontinuation 9 612 versus 187 PM-HK 2.96 1.14 to 7.66 48 0.31 to 27.89 
Treatment discontinuation (sensitivity†) 6 368 versus 160 PM-HK 3.62 1.05 to 12.51 57 0.41 to 26.13 
Treatment discontinuation  
(subgroup: hepatic) 6 255 versus 102 
BBIN 2.55 0.66 to 9.93 44 0.26 to 29.04 Peto 2.82 1.60 to 4.98 
Treatment discontinuation  
[subgroup: (hepato-)neurologic] 4 153 versus 33 
BBIN 4.49 0.42 to 48.0 70 0 to 8.7 x 103 Peto NA NA 
† sensitivity analysis for studies rated NOS ≥ 6; primary outcomes shown in bold, secondary outcomes in non-bold characters 
BBIN, Beta-binomial model; CI, confidence interval; NA, not applicable; NOS, Newcastle-Ottawa scale; OR, odds ratio; Peto, Yusuf-Peto 
method; PM-HK, Paule-Mandel estimator with modified Hartung-Knapp confidence intervals 
Note: We used PM-HK whenever there were at least 6 studies to pool or for sensitivity analyses of PM-HK analyses, we used BBIN 
whenever there were outcomes with 0 events or less than 6 studies. We did not use Peto when I2 was > 50%. We did not calculate 
prediction intervals when I2 was 0%.
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Figure legends 
Figure 1: Study flow diagram for the selection of studies. 
Figure 2: Meta-analysis of DPen versus no treatment. Effect of DPen versus no treatment on all-cause 
mortality. Summary odds ratio derived from beta-binomial model (BBIN); box sizes reflect the 
weights of the fixed-effect inverse variance model (IV). 
Figure 3: Meta-analyses of DPen versus Zn treatment. (A) Effect of DPen versus Zn treatment on all-
cause mortality. Summary odds ratio derived from beta-binomial model (BBIN); box sizes reflect the 
weights of the fixed-effect inverse variance model (IV). (B) Effect of DPen versus Zn treatment on 
prevention, remission, or amelioration of clinical symptoms (asymptomatic/improved). Performed 
with inverse-variance (IV) random effects meta-analysis using the Paule-Mandel between study 
heterogeneity estimator with modified Hartung-Knapp confidence intervals. 
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Additional 
records identified 
through other 
sources 
(n = 3) 
Records after duplicates removed 
(n = 3453) 
Records screened on 
title/abstract 
(n = 3453) 
Records excluded 
(n = 3279) 
Full-text articles assessed 
for eligibility 
(n = 174) 
Full-text articles excluded  
(n = 148) 
[Wrong study design (e.g. 
uncontrolled, case report, 
review) (n = 67) 
No patient-relevant outcome 
(n = 13) 
Incomplete reporting (n = 4) 
Conference abstracts (n = 58) 
Database duplicates (n = 6)] 
 
Articles included in 
qualitative synthesis 
(n = 26; reporting on 23 
studies) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 15) 
Update search  
(n = 190) 
[Medline+Embase 
(Ovid) (n = 178) 
CENTRAL (n = 12)] 
Total (95% CI)                  125                   56 0.01 [0; 0.17]    BBIN
Comparison: DPen versus no treatment
Outcome: mortality
DPen no treatment
AB
Comparison: DPen versus Zn
Outcome: mortality
DPen Zn
Total (95% CI)                       454                 236  0.74 [0.16; 3.48]        BBIN
Comparison: DPen versus Zn
Outcome: asymptomatic/improved
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Appendices 
Appendix 1: Search strategies 
MEDLINE (Ovid) 
November 30, 2017 
1. (Wilson disease or wilsons disease or Wilson s disease or wilson syndrome or wilson degenerat* or 
morbus wilson or Kinnier-Wilson or Kinnier-Wilsons or Kinnier-Wilson s or Pseudosclerosis or 
Westphal-Strumpell or Copper Storage Disease or Cerebral Pseudosclerosis or Cerebral 
Pseudoscleroses or hld or ((Hepatolenticular or Hepatocerebral or Neurohepatic or (Progressive and 
Lenticular)) and (Degenerat* or Syndrome))).ab,ti.   
2. (3 mercaptovaline or 3,3 dimethylcysteine or adaleen or alpha amino beta methyl beta 
mercaptobutyric acid or alpha penicillamin or artamin or atamir or beta mercaptovaline or beta,beta 
dimethylcysteamine or beta,beta dimethylcysteine or byanodine or cuprenil or cuprim or cuprimin or 
cuprimine or cuprimune or cupripen or d 3 mercaptovaline or d penicillamin or d penicillamine or d 
penicillamine hydrochloride or d penicillinamine hydrochloride or d-penamine or d-penil or delta 
penicillamine or depen or dextro penicillamine or dextropenicillamine or dimethyl cysteine or 
dimethylcysteine or distamine or dl penicillamine or gerodyl or kelatin or kelatine or l penicillamine or 
mercaptyl or metalcaptase or pemine or pendramine or penicilamina or penicillame or penicillamin or 
penicillamin d or penicillamine d or penicillamine hydrochloride or penicillinamine or racemic 
penicillamine or Penicillaminate or sufortanon or trolovol).ab,ti.   
3. (1,8 diamino 3,6 diazaoctane or 3,6 diazaoctane 1,8 diamine or cuprid or laszarin or "mk 0681" or 
mk 681 or mk0681 or mk681 or syprine or teta or trien or trientine dihydrochloride or trientine 
hydrochloride or trientine tetrahydrochloride or triethylene tetraamine or triethylene tetramide or 
triethylene tetramine or triethylenetetraamine or triethylenetetraamine dihydrochloride or 
triethylenetetramine or triethylenetetramine dihydrochloride).ab,ti.   
4. (tetrathiomolybdate or TTM cpd or thiomolybdate or ATN-224 or WTX101).ab,ti.   
5. (zinc or 64Zn or zincum or Zn or galzin or wilzin or zincasate or zinnax or op thal zin or solvazinc or 
solvezinc or verazinc or zincomed or zincteral).ab,ti.   
6. exp Hepatolenticular Degeneration/   
7. exp Penicillamine/   
8. exp Trientine/   
9. tetrathiomolybdate.nm.   
10. exp Zinc Acetate/ or exp Zinc/ or exp Zinc Sulfate/   
11. 1 or 6   
12. 2 or 7   
13. 3 or 8   
14. 4 or 9   
15. 5 or 10   
16. 12 or 13 or 14 or 15   
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17. 11 and 16   
18. Animals/   
19. Humans/   
20. 17 not (18 not 19) 
 
Embase (Ovid) 
November 30, 2017 
1. (Wilson disease or wilsons disease or Wilson s disease or wilson syndrome or wilson degenerat* or 
morbus wilson or Kinnier-Wilson or Kinnier-Wilsons or Kinnier-Wilson s or Pseudosclerosis or 
Westphal-Strumpell or Copper Storage Disease or Cerebral Pseudosclerosis or Cerebral 
Pseudoscleroses or hld or ((Hepatolenticular or Hepatocerebral or Neurohepatic or (Progressive and 
Lenticular)) and (Degenerat* or Syndrome))).ab,ti.   
2. (3 mercaptovaline or 3,3 dimethylcysteine or adaleen or alpha amino beta methyl beta 
mercaptobutyric acid or alpha penicillamin or artamin or atamir or beta mercaptovaline or beta,beta 
dimethylcysteamine or beta,beta dimethylcysteine or byanodine or cuprenil or cuprim or cuprimin or 
cuprimine or cuprimune or cupripen or d 3 mercaptovaline or d penicillamin or d penicillamine or d 
penicillamine hydrochloride or d penicillinamine hydrochloride or d-penamine or d-penil or delta 
penicillamine or depen or dextro penicillamine or dextropenicillamine or dimethyl cysteine or 
dimethylcysteine or distamine or dl penicillamine or gerodyl or kelatin or kelatine or l penicillamine or 
mercaptyl or metalcaptase or pemine or pendramine or penicilamina or penicillame or penicillamin or 
penicillamin d or penicillamine d or penicillamine hydrochloride or penicillinamine or racemic 
penicillamine or Penicillaminate or sufortanon or trolovol).ab,ti.   
3. (1,8 diamino 3,6 diazaoctane or 3,6 diazaoctane 1,8 diamine or cuprid or laszarin or "mk 0681" or 
mk 681 or mk0681 or mk681 or syprine or teta or trien or trientine dihydrochloride or trientine 
hydrochloride or trientine tetrahydrochloride or triethylene tetraamine or triethylene tetramide or 
triethylene tetramine or triethylenetetraamine or triethylenetetraamine dihydrochloride or 
triethylenetetramine or triethylenetetramine dihydrochloride).ab,ti.   
4. (tetrathiomolybdate or TTM cpd or thiomolybdate or ATN-224 or WTX101).ab,ti.   
5. (zinc or 64Zn or zincum or Zn or galzin or wilzin or zincasate or zinnax or op thal zin or solvazinc or 
solvezinc or verazinc or zincomed or zincteral).ab,ti.   
6. exp Wilson Disease/   
7. exp Penicillamine/   
8. exp Trientine/   
9. exp Tetrathiomolybdic Acid/   
10. exp Zinc Acetate/ or exp Zinc/ or exp Zinc Sulfate/   
11. 1 or 6   
12. 2 or 7   
13. 3 or 8   
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14. 4 or 9   
15. 5 or 10   
16. 12 or 13 or 14 or 15   
17. 11 and 16   
18. Animal/   
19. Human/   
20. 17 not (18 not 19) 
 
CENTRAL 
November 30, 2017 
Issue 10 
#1 Wilson disease or wilsons disease or Wilson s disease or wilson syndrome or wilson degenerat* 
or morbus wilson or Kinnier-Wilson or Kinnier-Wilsons or Kinnier-Wilson s or Pseudosclerosis or 
Westphal-Strumpell or Copper Storage Disease or Cerebral Pseudosclerosis or Cerebral 
Pseudoscleroses or hld or ((Hepatolenticular or Hepatocerebral or Neurohepatic or (Progressive and 
Lenticular)) and (Degenerat* or Syndrome)):ti,ab,kw  
#2 3 mercaptovaline or 3,3 dimethylcysteine or adaleen or alpha amino beta methyl beta 
mercaptobutyric acid or alpha penicillamin or artamin or atamir or beta mercaptovaline or beta,beta 
dimethylcysteamine or beta,beta dimethylcysteine or byanodine or cuprenil or cuprim or cuprimin or 
cuprimine or cuprimune or cupripen or d 3 mercaptovaline or d penicillamin or d penicillamine or d 
penicillamine hydrochloride or d penicillinamine hydrochloride or d-penamine or d-penil or delta 
penicillamine or depen or dextro penicillamine or dextropenicillamine or dimethyl cysteine or 
dimethylcysteine or distamine or dl penicillamine or gerodyl or kelatin or kelatine or l penicillamine or 
mercaptyl or metalcaptase or pemine or pendramine or penicilamina or penicillame or penicillamin or 
penicillamin d or penicillamine d or penicillamine hydrochloride or penicillinamine or racemic 
penicillamine or Penicillaminate or sufortanon or trolovol:ti,ab,kw  
#3 1,8 diamino 3,6 diazaoctane or 3,6 diazaoctane 1,8 diamine or cuprid or laszarin or mk 0681 or 
mk 681 or mk0681 or mk681 or syprine or teta or trien or trientine dihydrochloride or trientine 
hydrochloride or trientine tetrahydrochloride or triethylene tetraamine or triethylene tetramide or 
triethylene tetramine or triethylenetetraamine or triethylenetetraamine dihydrochloride or 
triethylenetetramine or triethylenetetramine dihydrochloride:ti,ab,kw  
#4 tetrathiomolybdate or TTM cpd or thiomolybdate or ATN-224 or WTX101:ti,ab,kw  
#5 zinc or 64Zn or zincum or Zn or galzin or wilzin or zincasate or zinnax or op thal zin or solvazinc 
or solvezinc or verazinc or zincomed or zincteral:ti,ab,kw  
#6 MeSH descriptor: [Hepatolenticular Degeneration] explode all trees 
#7 MeSH descriptor: [Penicillamine] explode all trees 
#8 MeSH descriptor: [Trientine] explode all trees 
#9 MeSH descriptor: [Zinc] explode all trees 
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#10 MeSH descriptor: [Zinc Sulfate] explode all trees 
#11 MeSH descriptor: [Zinc Acetate] explode all trees 
#12 (#1 or #6) and (#2 or #3 or #4 or #5 or #7 or #8 or #9 or #10 or #11)  
#13 MeSH descriptor: [Animals] explode all trees 
#14 MeSH descriptor: [Humans] explode all trees 
#15 #12 not (#13 not #14) 
 
Update search 
January 31, 2019 
The above Ovid search strategies were combined (with MeSH and Emtree terms combined with OR), 
and search results from Medline and Embase directly deduplicated in Ovid. This search was limited to 
01 January 2017 to 31 January 2019. 
The search strategy for CENTRAL was rerun in the Cochrane library. The search time range was not 
limited. 
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Supporting Information 
Supporting Tables 
Table S1: Characteristics of 144 excluded studies [ordered by first-author 
names] 
Note that de Bem 2011, Fadda 2012, Leiros Da Costa 2009, and Silva 1996 are database duplicates, 
explaining the difference between 144 versus 148 excluded studies (compare to Figure 1).  
 
Study Reason for exclusion 
Abdel Ghaffar 20111 Wrong study design (analysis of outcome not linked to treatment) 
Aggarwal 20142 Conference abstract 
Aggarwal 20173 Conference abstract 
Al Fadda 20124 Wrong study design (uncontrolled) 
Alam 20135 Conference abstract 
Aposhian 19716 Wrong study design (review) 
Arnon 20077 Wrong study design (uncontrolled) 
Askari 20038 Wrong study design (uncontrolled) 
Avan 20139 Conference abstract 
Avan 201510 Conference abstract 
Avinashi 200911 Conference abstract 
Bachmann 198912 Wrong study design (uncontrolled) 
Baeg 201513 Conference abstract 
Bagchi 201214 Conference abstract 
Barbosa 199115 Wrong study design (uncontrolled) 
Beinhardt 201216 Conference abstract 
Bem 201117 Wrong study design (analysis of outcome not linked to treatment) 
Berenguer 201718 Conference abstract 
Bono 200219 Wrong study design (analysis of outcome not linked to treatment) 
Brewer 199520 Wrong study design (review) 
Brewer 199621 Wrong study design (uncontrolled) 
Brewer 199722 Wrong study design (uncontrolled) 
Brewer 200323 Wrong study design (uncontrolled) 
Brewer 200624 Database duplicate (included article) 
Brewer 200825 Database duplicate (included article) 
Burke 201126 Wrong study design (analysis of outcome not linked to treatment) 
Chu 199327 Wrong study design (review) 
Cossack 198628 No patient-relevant outcome (copper balance) 
Czlonkowska 201029 Conference abstract 
Czlonkowska 201330 Conference abstract 
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Czlonkowska 201531 Conference abstract 
da Costa Mdo 200932 Incomplete reporting of treatment regimen 
Dastych 201033 No patient-relevant outcome (Elements in serum, urine, and hair) 
de Bem 2011 Database duplicate (see Ref. 17) 
De Sousa 201734 Conference abstract 
Deiss 197135 Wrong study design (uncontrolled) 
Demir 201436 Conference abstract 
Denny-Brown 196437 Wrong study design (case series) 
Dubbioso 201638 Wrong study design (neurological vs. non-neurological) 
Dziezyc 201439 No patient-relevant outcome (compliance) 
El Machkour 201140 Wrong study design (case series) 
El-Karaksy 201141 Wrong study design (analysis of outcome not linked to treatment) 
Engelbrecht 199542 Wrong study design (case report) 
Esposito 201343 Conference abstract 
Estevo 201244 Conference abstract 
Fadda 200945 Conference abstract 
Fadda 2012 Database duplicate (see Ref. 4) 
Gill 199446 Wrong study design (case series) 
Girardot-Tinant 201247 Conference abstract 
Goldstein 196348 No patient-relevant outcome (copper balance) 
Goldstein 196549 No patient-relevant outcome (copper balance) 
Gromadzka 201450 No patient-relevant outcome (antioxidant capacity) 
Gupta 201751 Conference abstract 
Gupta 201852 Wrong study design (uncontrolled) 
Harders 197753 Wrong study design (case report) 
Hefter 201854 Incomplete reporting of treatment regimen 
Hill 198655 Wrong study design (mechanistic) 
Hoogenraad 198756 Wrong study design (uncontrolled) 
Hsia 196657 No patient-relevant outcome (copper balance) 
Hui 201158 Conference abstract 
Idrissi 201359 Wrong study design (analysis of outcome not linked to treatment) 
Jablonska 200360 Wrong study design (uncontrolled) 
Janczyk 200961 Conference abstract 
Janczyk 201662 Conference abstract 
Janczyk 201763 Conference abstract 
Kalita 201464 Wrong study design (analysis of outcome not linked to treatment) 
Kalita 201565 Wrong study design (analysis of outcome not linked to treatment) 
Kalra 200066 Wrong study design (uncontrolled) 
Kazemi 200867 Wrong study design (cross-sectional) 
Kleine 201268 Wrong study design (uncontrolled) 
Kondou 201369 Conference abstract 
Kucinskas 200870 Wrong study design (genetic study) 
Kumar 201071 Conference abstract 
Kumar 2012a72 Conference abstract 
Kumar 2012b73 Conference abstract 
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Kunath 200374 Wrong study design (analysis of outcome not linked to treatment) 
Lapeyre 201075 Conference abstract 
Leiros Da Costa 2009 Database duplicate (see Ref. 32) 
Lingam 198776 Wrong study design (case series) 
Lossner 198077 Wrong study design (uncontrolled) 
Manolaki 200978 Wrong study design (analysis of outcome not linked to treatment) 
Medici 200779 No patient-relevant outcome (hepatic iron concentration) 
Mercier-Jacquier 201180 Wrong study design (uncontrolled) 
Moores 201081 Conference abstract 
Moores 201182 Conference abstract 
Moores 201283 Incomplete reporting 
Ogihara 199584 No patient-relevant outcome (antioxidant capacity) 
Osborn 195885 No patient-relevant outcome (copper excretion) 
Park 199186 Wrong study design (analysis of outcome not linked to treatment) 
Parkash 2012a87 Conference abstract 
Parkash 2012b88 Conference abstract 
Pellecchia 200389 Wrong study design (analysis of outcome not linked to treatment) 
Pfeiffenberger90 No patient-relevant outcome (urinary and serum copper levels) 
Pietrobattista 201091 Conference abstract 
Poujois 201692 Conference abstract 
Poujois 201893 Wrong study design (cross-sectional) 
Ramachandiran 201294 Conference abstract 
Ranucci 201195 Conference abstract 
Ranucci 201296 Conference abstract 
Ranucci 201397 Conference abstract 
Ranucci 201698 Conference abstract 
Ras 201099 Conference abstract 
Richmond 1964100 Wrong study design (case series) 
Rodrigo Agudo 2008101 Wrong study design (analysis of outcome not linked to treatment) 
Saito 1991102 Wrong study design (uncontrolled) 
For the controlled part: No patient-relevant outcome (urinary copper 
excretion) 
Sanchez 1997103 Wrong study design (uncontrolled) 
Santiago 2015104 Wrong study design (uncontrolled) 
Santos Silva 1996105 Wrong study design (analysis of outcome not linked to treatment) 
Sarapura 2017106 Conference abstract 
Scheinberg 1987107 Wrong study design (drug continuation vs discontinuation) 
Schilsky 1991108 Wrong study design (uncontrolled) 
Schlaug 1996109 Wrong study design (analysis of outcome not linked to treatment) 
Seesle 2012110 Conference abstract 
Seignette 1959111 Wrong study design (case series) 
Shahar 2013112 Conference abstract 
Silva 1996 Database duplicate (see Ref. 99) 
Sinha 2006113 Incomplete reporting of treatment regimen 
Sinha 2008114 Wrong study design (uncontrolled) 
Sintusek 2016115 Wrong study design (uncontrolled) 
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Sobesky 2016116 Conference abstract 
Sobesky 2017117 Conference abstract 
Soyer 2014118 Conference abstract 
Starosta-Rubinstein 1987119 Wrong study design (uncontrolled) 
Strickland 1971120 No patient-relevant outcome (copper balance) 
Tai 2016121 Conference abstract 
Taly 2007122 Wrong study design (analysis of outcome not linked to treatment) 
Taylor 2009123 Wrong study design (uncontrolled) 
Teive 2012124 Conference abstract 
Trocello 2010125 Conference abstract 
Valmary 1992126 Conference abstract 
Van Caillie-Bertrand 1985127 Wrong study design (uncontrolled) 
Vandriel 2017128 Conference abstract 
Viswanathan 2009129 Conference abstract 
Walshe 1973130 No patient-relevant outcome (serum and urinary copper) 
Walshe 1982131 Wrong study design (uncontrolled) 
Walshe 1993132 Wrong study design (analysis of outcome not linked to treatment) 
Walshe 2007133 Wrong study design (analysis of outcome not linked to treatment) 
Wang 2010134 Wrong study design (analysis of outcome not linked to treatment) 
Wang 2016135 Conference abstract 
Weiss 2011a136 Conference abstract 
Weiss 2011b137 Conference abstract 
Wiernicka 2013138 Wrong study design (uncontrolled) 
Wiernicka 2017139 Wrong study design (analysis of outcome not linked to treatment) 
Wu 2014140 Conference abstract 
Xu 2013141 Wrong study design (alternating regimen) 
Yuce 2000142 Wrong study design (uncontrolled) 
Yuce 2010143 Conference abstract 
Zhang 2018144 Wrong study design (wrong comparator) 
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Table S2: Results of quality assessment using the Newcastle-Ottawa Scale for cohort studies and the RoB 2.0 tool for 
randomized controlled trials 
Newcastle-Ottawa Scale 
FIRST 
AUTHOR, 
YEAR 
REPRESENTATIVE-
NESS OF THE 
EXPOSED COHORT 
SELECTION 
OF THE 
NON-
EXPOSED 
COHORT 
ASCERTAINMENT 
OF EXPOSURE 
DEMONSTRATION 
THAT OUTCOME 
OF INTEREST WAS 
NOT PRESENT AT 
START OF STUDY 
COMPARABILITY 
OF COHORTS 
ON THE BASIS 
OF THE DESIGN 
OR ANALYSIS 
ASSESSMENT 
OF 
OUTCOME 
FOLLOW-
UP LENGTH 
IN 
RELATION 
TO 
OUTCOME 
INCIDENCE 
ADEQUACY 
OF 
FOLLOW-
UP OF 
COHORTS 
TOTAL 
SCORE 
Goldstein, 
1968 
        7 
Sternlieb, 
1968 
        5 
Strickland, 
1973 
        4 
Durand, 
2001 
        5 
          
Weiss, 2011 
 
        5 
Sini, 2013 
 
        7 
Seessle, 
2016 
        5 
Tai, 2018         6 
          
Czlonkowska
, 1996 
        7 
10 
 
Iorio, 2004 
 
        6 
Czlonkowska
, 2005 
        5 
Medici, 2006 
 
        6 
Svetel, 2009 
 
        4 
Cope-
Yokoyama, 
2010 
        
6 
Bruha, 2011 
 
        6 
Rodriguez, 
2012 
        4 
Ranucci, 
2014 
        4 
Czlonkowska
, 2014 
        8 
Vieira 
Barbosa, 
2018 
        
4 
          
Kumagi, 
2004 
        2 
Weiss, 2013 
 
        6 
          
Ren, 1998 
 
        6 
 Score 1 point,   Score 0 point. 
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RoB 2.0 tool for randomized controlled trials 
FIRST 
AUTHOR, 
YEAR 
BIAS ARISING FROM 
THE RANDOMIZATION 
PROCESS 
BIAS DUE TO DEVIATIONS 
FROM INTENDED 
INTERVENTIONS 
BIAS DUE TO 
MISSING 
OUTCOME DATA 
BIAS IN MEASUREMENT 
OF THE OUTCOME 
BIAS IN SELECTION OF 
THE REPORTED 
RESULT 
OVERALL BIAS 
       
Brewer, 2006       
 Low risk of bias  Some concerns  High risk of bias 
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Table S3: Overview of outcome events per included study 
Overview for mortality, asymptomatic, asymptomatic/improved, OLT, side effects, (irreversible) neurologic 
deterioration, and treatment discontinuation 
 Clinical 
presentation: 
Mortality Asymptomatic Asymptomatic/ 
improved 
OLT Side effects Neurologic 
deterioration 
[irreversible] 
Treatment discontinuation 
[reasons] 
D-Penicillamine versus no treatment: Number of patients with event / Total number of patients (%) 
Goldstein, 
1968 
presymptomatic  
hepatic  
hepato-neurologic  
neurologic  
0/2 (0) vs. 0/0 (0) 
0/1 (0) vs. 1/1 (100) 
1/4 (25) vs. 1/1 (100) 
1/14 (7) vs. 0/0 (0) 
2/2 (100) vs. 0/0 (0) 
0/1 (0) vs. 0/1 (0) 
0/4 (0) vs. 0/1 (0) 
2/14 (100) vs. 0/0 (0) 
2/2 (100) vs. 0/0 (0) 
1/1 (100) vs. 0/1 (0) 
3/4 (75) vs. 0/1 (0) 
14/14 (100) vs. 0/0 (0) 
 
   
Sternlieb, 
1968 
presymptomatic 0/42 (0) vs. 6/11 (55) 
 
 
42/42 (100) vs. 0/11 (0) 
 
 
 
   
Strickland, 
1973 
presymptomatic 
symptomatic 
1/16 (6) vs. 0/1 (0) 
4/35 (11) vs. 35/36 (100) 
15/16 (94) vs. 1/1 (100) 
18/35 (51) vs. 0/36 (0) 
 
 
   
Durand, 2001 hepatic  0/11 (0) vs. 5/6 (83) 
  
1/11 (9) vs. 2/6 (33) 
   
D-Penicillamine versus trientine versus zinc salts: Number of patients with event / Total number of patients (%) 
Weiss, 2011† 
(Merle, 2007) 
presymptomatic  
hepatic  
hepato-neurologic  
neurologic 
all presentations: 
1/220 (0) vs. 0/24 (0) vs. 
1/23 (4%) 
 
16/29 (55) vs. 1/1 (100) vs. 0/0 (0) 
85/131 (65) vs. 8/13 (62) vs. 13/18 
(72) 
8/19 (42) vs. 2/5 (40) vs. 0/0 (0) 
16/41 (39) vs. 4/5 (80) vs. 3/5 (60) 
 
 all presentations: 
147/220 (67) vs. 8/24 (33) 
vs. 7/23 (30) 
NA 
NA 
 
13/60 (22) vs. 1/10 (10) vs. 
1/5 (20) 
13/29 (45) [10 SE, 3 other] vs. 0/1 (0) 
46/131 (35) [25 SE, 21 other] vs. 5/13 (38) [1 SE, 4 other] vs. 5/18 (28) 
[3 TF, 2 other] 
11/19 (58) [8 SE, 3 other] vs. 3/5 (60) [3 SE] 
25/41 (61) [21 SE, 4 other] vs. 1/5 (20) [1 other] vs. 2/5 (40) [1 SE, 1 TF] 
(hepatic TF not recorded) 
Tai,  2018 any       29/54 (54) vs. 0/4 (0) vs. 0/8 (0) 
D-Penicillamine versus zinc salts: Number of patients with event / Total number of patients (%) 
Czlonkowska, 
1996 
presymptomatic  
hepatic  
neurologic 
0/3 (0) vs. 0/8 (0%) 
3/31 (10) vs 4/25 (16)  
(hepatic or neurologic 
presentation) 
 
2/2 (100) vs. 8/8 (100) 
11/17 (65) vs. 15/21 (71) (hepatic or 
neurologic patients) 
 all presentations: 
10/34 (29) vs. 2/33 (6) 
 
all presentations: 
15/34 (44) [10 SE, 5 TF] vs. 4/33 (12) [2 SE, 2 TF] 
Iorio, 2004 presymptomatic  
hepatic  
neurologic 
  
all presentations: 
58/87 (67) vs. 11/22 (50) 
all presentations: 
1/87 (1) vs. 0/22 (0) 
all presentations: 
5/87 (6) vs. 0/22 (0) 
 
all presentations: 
17/87 (20) [5 SE, 12 TF] vs. 5/22 (23) [5 TF] 
Czlonkowska, 
2005 
any 10/79 (13) vs. 8/81 (10) 
  
 
   
Medici, 2006 hepatic  
hepato-neurologic  
0/15 (0) vs.  0/8 (0) 
1/8 (13) vs. 1/4 (25) 
 
7/15 (47) vs. 5/8 (63) 
2/8 (25) vs. 2/4 (75) 
1/15 (7) vs.  1/8 (0) 
0/8 (0) vs. 2/4 (50) 
all presentations: 
6/23 (26) vs. 4/12 (33) 
NA 
6/8 (75) vs. 0/4 (0) 
8/15 (53) [4 SE, 4 TF] vs. 2/8 (25) [2 TF] 
8/8 (100) [2 SE,  6 END] vs. 0/4 (0%)  
Bruha, 2011 presymptomatic  
hepatic  
neurologic 
  
8/8 (100) vs. 2/2 (100) 
26/34 (76) vs. 7/8 (88) 
26/38 (68) vs. 2/3 (67) 
 all presentations: 
35/99 (35) vs. 0/13 (0) 
 
treatment discontinuation 
1/9 (11) [1 SE] vs. 0/2 (0) 
6/40 (15) [3 SE, 3 other] vs. 0/8 (0) 
21/50 (42) [8 SE, 10 TF, 3 other] vs. 0/3 (0) 
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Rodriguez, 
2012 
presymptomatic  
hepatic  
hepato-neurologic  
neurologic 
  
all presentations: 
11/18 (61) vs. 2/2 (100) 
0/0 (0) vs. 0/2 (0) 
1/10 (10) vs. 0/0 (0) 
0/3 (0) vs. 0/0 (0) 
0/5 (0) vs. 0/0 (0) 
 
 
all presentations: 
4/18 (22) vs. NR 
 
all presentations: 
13/18 (72) [4 SE, 3 TF, 6 other] vs. 0/2 (0) 
Ranucci, 2014 hepatic  0/27 (0) vs. 0/15 (0) 
 
20/27 (74) vs. 13/15 (87) 0/27 (0) vs. 0/15 (0) 10/27 (37) vs. 13/15 (87) 3/27 (11) vs. 0/15 (0) 19/27 (70) vs. 2/15 (13) 
Czlonkowska, 
2014 
(Litwin, 2015) 
hepatic  
neurologic 
0/36 (0) vs. 0/51 (0) 
4/35 (11) vs. 1/21 (5) 
 
34/36 (94) vs. 48/51 (94) 
29/35 (83) vs. 15/21 (71) 
 
 
NA 
12/35 (34) [4 (12)] vs. 4/21 
(19) [1 (5)] 
11/36 (31) vs. 6/51 (12) 
7/35 (20) [11 SE, 2 TF, 3 END, 2 other] vs. 5/21 (24) [2 SE, 6 TF, 3 END] 
Vieira 
Barbosa, 
2018 
hepatic 0/6 (0) vs. 0/2 (0)   3/6 (50) vs. 0/2 (0)   3/6 (50) [3 SE] vs. 2/2 (100) [2 other] 
D-Penicillamine versus trientine: Number of patients with event / Total number of patients (%) 
Kumagi, 2004 presymptomatic  
hepatic  
hepato-neurologic  
all presentations: 
2/15 (13) vs. 0/1 (0) 
  
0/1 (0) vs. 0/0 (0) 
0/10 (0) vs. 1/1 (100) 
0/4 (0) vs. 0/0 (0) 
0/1 (0) vs. 0/0 (0) 
2/10 (20) vs. 1/1 (100) 
1/4 (25) vs. 0/0 (0) 
 
0/1 (0) vs. 0/0 (0) 
2/10 (20) [2 SE] vs. 0/1 (0) 
1/4 (25) [1 SE] vs. 0/0 (0) 
Weiss, 2013† presymptomatic  
hepatic  
hepato-neurologic  
neurologic 
  
32/48 (67) vs. 2/2 (100) 
88/150 (59) vs. 14/20 (70) 
12/31 (39) vs. 6/7 (86) 
32/66 (48) vs. 7/9 (78) 
 all presentations: 
182/295 (62) vs. 9/38 (24) 
NA 
NA 
 
8/97 (8) vs. 5/16 (31) 
15/48 (31) [13 SE, 2 other] vs. 0/2 (0) 
62/150 (41) [3 TF, 41 SE, 18 other] vs. 6/20 (30) [1 TF, 1 SE, 4 other]  
19/31 (61) [1 TF, 16 SE, 2 other] vs. 1/7 (14) [1 other] 
34/66 (52) [26 SE, 8 other] vs. 2/9 (22) [1 SE, 1 other]  
(only hepatic TF analyzed) 
D-Penicillamine (+ Zn-gluconate) versus succimer (+ Zn-gluconate): Number of patients with event / Total number of patients (%) 
Ren, 1998 presymptomatic  
hepatic  
neurologic 
  
all presentations: 
35/60 (58) vs. 49/60 (82) 
 all presentations: 
22/60 (37) vs. 9/60 (15) 
 
all presentations: 
25/60 (42) [25 TF] vs. 11/60 (18) [11 TF 
Trientine (+ Zn-acetate) versus tetrathiomolybdate (+ Zn-acetate): Number of patients with event / Total number of patients (%) 
Brewer, 2006 
(Brewer, 
2008) 
neurologic 0/23 (0) vs. 0/25  (0) 
(6 pat died under Zn 
maintenance; FU 6-22 mo) 
  
 1/23 (4) vs. 7/25 (28) 6/23 (26) vs. 1/25 (4) 
 
† outcome data unpublished; available on request;  
END, early neurologic deterioration; FU, follow-up; NA, not applicable; NR, not reported; OLT, orthotopic liver transplantation; pat, patient; SE, side effect; TF treatment failure; Zn, zinc 
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Table S4: First choice recommendations by study authors comparing chelator (DPen, trientine) and Zn treatments 
Patients Hepatic† Neurologic† Presymptomatic† Pediatric 
Therapy I M I M I M I M 
AASLD145 
Chelator Chelator or Zn Chelator 
Chelator 
or Zn 
Chelator 
or Zn 
Chelator 
or Zn - - 
EASL146 
Chelator - Chelator (or Zn) 
Chelator 
or Zn 
Chelator 
or Zn 
Chelator 
or Zn - - 
INASL147 
Chelator Chelator or Zn 
Chelator 
or Zn 
Chelator 
or Zn 
Chelator 
or Zn 
Chelator 
or Zn - - 
ESPGHAN148 
- - - - - - Chelator or Zn‡ Zn 
         
Czlonkowska, 1996149 - - Zn - Zn - - - 
 "Long-term observation of a relatively large group of patients permits us to consider Zn as the drug of 
first choice for the initiation of treatment in patients with neurological and preclinical forms of WD. To 
be able to answer the question as to whether Zn or D-P is more effective in the hepatic form of the 
disease or for specific neurological signs, more extensive observation is required, (…)" 
Medici, 2006150 DPen - Zn - Zn - - - 
 "D-PCA is effective in treating WD without related neurologic symptoms, whereas zinc could effectively 
replace D-PCA in the event of side effects and we suggest it as first-line therapy in cases with neurologic 
symptoms, in presymptomatic subjects and during pregnancy." 
Merle, 2007151 - - Trientine or Zn - - - - - 
 "(…) in our opinion, D-penicillamine should not be the drug of choice for patients with neurological 
symptoms." 
Bruha, 2011152 DPen - Zn - - - - - 
 "Our study confirms the good efficacy of zinc salts in patients with neurological WD, and of D -
penicillamine in those patients with the hepatic form of WD (…)" 
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Weiss, 2011153 
chelator - Chelator or Zn - 
Chelator 
or Zn - - - 
 "In conclusion, the primary role of zinc monotherapy may remain as a medical treatment alternative for 
asymptomatic or neurologically affected patients." 
Rodriguez, 2012154 DPen DPen or Zn DPen 
DPen or 
Zn 
DPen or 
Zn 
DPen or 
Zn - - 
 "In our series, d-penicillamine was the drug mostly used, particularly in those who were symptomatic at 
diagnosis. In patients at pre-symptomatic stages or on maintenance therapy, chelators or Zn are 
potential alternatives." 
Czlonkowska, 2014155 DPen or 
Zn - Zn - 
DPen or 
Zn - - - 
 "Adjusted analysis showed that neurological WD patients treated with first-line DPA may be potentially 
more prone to experience early worsening. (…) Therefore, because of their different and slower 
mechanism of action, zinc salts may seem safer in patients with neurological WD. (…) ZS may 
be considered a reasonable alternative to DPA as first-line therapy in all WD patients, not only in those 
less affected or asymptomatic." 
Ranucci, 2014156 - - - - - - Zn Zn 
 "Zinc monotherapy is effective in controlling WD-related liver disease both as first-line and as 
maintenance treatment in patients with mild liver disease diagnosed in childhood." 
† All ages; ‡ Chelator for hepatic presentation, Zn for presymptomatic presentation; AASLD, American Association for the Study of Liver Diseases; 
EASL, European Association for the Study of the Liver; ESPGHAN, European Society for Paediatric Gastroenterology, Hepatology and Nutrition; 
INASL, Indian National Association for Study of the Liver; I, initial; M, maintenance 
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Table S5: Statements on lack of correlation between elevated serum transaminases and liver disease 
 Wording 
Iorio, 2004157 
"No significant difference was found in basal histologic lesions between patients with persistent hypertransaminasemia and 
patients who normalized ALT on therapy." 
 
"Interestingly, despite longstanding hypertransaminasemia, no patient showed worsening of the liver disease or developed 
other Wilson’s disease-related symptoms." 
Medici, 2006150 "Twenty percent of our patients had longstanding mild hypertransaminasemia unresponsive to either D-PCA or zinc, but no sign of any progression of their liver disease." 
Cope-Yokoyama, 
2010158 
"There was  no  significant  correlation  between  the  histological findings  and  serum  aminotransferases  or  copper  
metabolism parameters." 
Weiss, 2011153 
"In patients with nonresponse to zinc therapy, an increase in liver enzyme levels was noted (Figure 2) compared with zinc 
responders. (…) The comparison of the time course of other laboratory values (alkaline phosphatase, choline esterase, 
international normalized ratio, bilirubin, serum copper, ceruloplasmin, non–ceruloplasmin-bound copper) revealed no 
statistically significant differences between the responder and nonresponder groups at any time point (data not shown)." 
Sini, 2013159 
"The need to carry out a follow-up of the histology features is further supported by the fact that in our study, the clinical 
course and histopathologic evolution of liver disease did not correlate with the laboratory data examined. (…) This is why 
biochemical parameters are not sufficient to assess the effectiveness of medical therapy on the evolution of liver disease, 
and we suggest the need to carry out a clinical follow-up and periodic histologic evaluation." 
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Supporting Figures 
 
Figure S1: Effect of DPen versus Zn treatment on side effects. Summary odds ratio derived from beta-
binomial model (BBIN); box sizes reflect the weights of the fixed-effect inverse variance model (IV). 
 
 
 
 
 
 
Figure S2: Effect of DPen versus Zn treatment on neurologic deterioration. Summary odds ratio derived 
from beta-binomial model (BBIN); box sizes reflect the weights of the fixed-effect inverse variance 
model (IV). Note that only Medici 2006 and Czlonkowska 2014 specifically reported on early neurologic 
deterioration.  
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Figure S3: Effect of DPen versus Zn treatment on treatment discontinuation. Performed with inverse-
variance (IV) random effects meta-analysis using the Paule-Mandel between study heterogeneity 
estimator with modified Hartung-Knapp confidence intervals. 
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